Counting Pills to Pay Rent: The Financial Crisis Quietly Undermining HIV Care in New York City

Marcos, a 47-year-old warehouse worker from the South Bronx, has been living with HIV for eleven years. He has never missed a viral load appointment, never ignored a prescription refill—until last winter, when his insurance lapsed between jobs and his copay assistance program informed him it had exhausted its annual funding. For six weeks, he rationed his antiretroviral medication, taking doses every other day rather than daily, hoping the gap would not undo years of careful adherence.

"I knew what I was doing was wrong," he said. "But I had to choose between the pills and the electricity bill. You can't take medication in the dark."

Marcos is not an outlier. Across New York City, a quiet financial emergency is undermining one of the most medically advanced HIV care ecosystems in the world. Treatments that can render the virus undetectable—and therefore untransmittable—exist. The infrastructure to deliver them exists. What increasingly does not exist, for a growing number of New Yorkers, is the financial pathway to actually access them without sacrificing other essentials of survival.

The Architecture of a Broken Safety Net

The United States does not have a unified system for subsidizing HIV medication costs. Instead, patients navigate a patchwork of programs—manufacturer copay cards, nonprofit assistance funds, state AIDS Drug Assistance Programs (ADAPs), and Medicaid—each with its own eligibility thresholds, enrollment windows, and funding caps.

New York's ADAP, administered through the AIDS Institute, remains one of the more robust in the country, covering antiretroviral medications for uninsured and underinsured residents who meet income guidelines. But enrollment is not automatic, documentation requirements can be burdensome, and the program does not cover every ancillary cost of HIV care—lab work, specialist visits, and mental health services that are inseparable from sustained treatment.

For those who do carry private insurance, copay assistance programs offered by pharmaceutical manufacturers have historically filled the gap between coverage and out-of-pocket costs. Those programs, however, have faced mounting pressure. Some insurers have implemented "copay accumulator" policies that prevent manufacturer assistance from counting toward a patient's annual deductible, effectively negating the benefit and leaving patients with unexpectedly high year-end costs. Federal guidance on accumulator programs has shifted with successive administrations, creating a regulatory environment that drug companies, insurers, and patients alike struggle to interpret consistently.

The result is a system in which a person can be technically insured, technically enrolled in an assistance program, and still find themselves unable to afford their medication.

Mid-Treatment Interruptions: A Medical and Human Crisis

The consequences of treatment interruption extend well beyond individual health outcomes. When a person living with HIV skips doses or stops treatment entirely, viral load can rebound—sometimes rapidly. This not only jeopardizes the individual's long-term prognosis but also eliminates the prevention benefit of Undetectable = Untransmittable (U=U), the principle that a person with an undetectable viral load cannot sexually transmit HIV to a partner.

Public health researchers have documented that financial barriers to medication adherence disproportionately affect Black and Latino New Yorkers, communities already facing higher rates of HIV diagnosis and fewer economic resources to absorb unexpected healthcare costs. A 2022 analysis by the New York City Department of Health and Mental Hygiene found that retention in HIV care—the sustained engagement necessary for viral suppression—remained significantly lower in high-poverty neighborhoods than in wealthier parts of the city, a disparity driven in no small part by cost-related barriers.

The human dimension of this data is difficult to overstate. Treatment interruption is not a personal failing. It is, in many cases, a rational response to an irrational system.

Insurance Gaps That Open Without Warning

For New Yorkers whose HIV care is tied to employer-sponsored insurance, job loss creates an immediate and dangerous vulnerability. COBRA continuation coverage exists in theory but costs hundreds of dollars per month—a figure that is unmanageable for most people who have just lost their income. The 60-day window to enroll in a Marketplace plan through the New York State of Health exchange following a qualifying life event can expire before a newly unemployed person has stabilized enough to navigate the enrollment process.

The gap between losing insurance and securing new coverage is not measured in bureaucratic inconvenience. It is measured in missed doses, in rebounding viral loads, in clinic visits that don't happen because there is no coverage to bill.

Navigators at community health centers across the five boroughs report that insurance-related interruptions are among the most common crises they manage—and among the most preventable, if patients knew to call before coverage lapsed rather than after.

What Resources Actually Exist Right Now

For New Yorkers currently struggling with medication costs, the following resources represent the most accessible entry points:

The New York ADAP (AIDS Drug Assistance Program): Administered by the New York State AIDS Institute, ADAP covers antiretroviral medications and select other HIV-related drugs for eligible residents. Income eligibility extends to 435 percent of the federal poverty level. Applications can be initiated through participating clinics or by calling 1-800-542-2437.

Ryan White HIV/AIDS Program: Federally funded and locally administered, Ryan White provides a range of services—including medication assistance, case management, and medical care—for low-income New Yorkers living with HIV who are uninsured or underinsured. NYC Health + Hospitals sites and many community health centers participate in Ryan White-funded programming.

Manufacturer Patient Assistance Programs: Most major antiretroviral manufacturers maintain programs for uninsured patients who meet income criteria. Gilead's Advancing Access program, ViiV Healthcare's Positive Action program, and Janssen's Patient Assistance Program are among the most widely used. A patient navigator or social worker can help identify the appropriate program and manage the application.

NYC Human Resources Administration (HRA) HIV/AIDS Services Administration (HASA): HASA provides a range of support services—including housing assistance, benefits navigation, and food support—for New Yorkers living with HIV who meet eligibility criteria. These supports can free up income that would otherwise be diverted from medication costs.

Community-Based Organizations: Organizations including Housing Works, GMHC, and Bailey House maintain staff specifically trained to help clients navigate insurance enrollment, benefit applications, and emergency medication assistance. These organizations can often move faster than institutional systems and provide the kind of sustained, relationship-based support that makes navigation possible.

The Policy Changes That Would Actually Solve This

Workarounds and emergency resources are not a substitute for structural reform. Advocates in New York and nationally have identified several policy changes that would meaningfully reduce medication-related financial hardship for people living with HIV.

Banning copay accumulator adjustment programs—or requiring that manufacturer assistance count toward deductibles—would restore the protective function these programs were designed to provide. Expanding Medicaid eligibility and auto-enrollment pathways would reduce the number of New Yorkers who fall uninsured during vulnerable transitions. Strengthening federal Ryan White funding, which has not kept pace with the true cost of comprehensive HIV care, would stabilize a program that remains a lifeline for hundreds of thousands of Americans.

At the state level, advocates have called on Albany to close remaining gaps in ADAP coverage, expand the program's scope to include additional ancillary services, and streamline enrollment to reduce documentation burdens that disproportionately screen out the people most in need.

Treatment Is Not a Luxury

Marcos eventually secured coverage through the New York State of Health exchange, with the help of a navigator at a Bronx community health center. His viral load, after the six-week interruption, had risen—not to dangerous levels, but enough to require closer monitoring for several months.

"The system treats medication like it's optional," he said. "Like it's something you earn. But this is my life."

The science of HIV treatment has advanced to a point where a person diagnosed today, with consistent access to care, can expect a near-normal lifespan. That promise is only as real as the financial infrastructure supporting it. For too many New Yorkers, that infrastructure is failing—not because the resources don't exist, but because they are distributed through a system designed more to manage liability than to ensure access.

Knowledge, care, and community are the foundation of what we do at AIDS NYC. But knowledge without access is cruelty dressed as information. Every New Yorker living with HIV deserves a path to treatment that does not require choosing between their health and their survival.